The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Cilique 250/35 micrograms tablets

Consilient Health LimitedPA1876/003/001

Main Information

Trade NameCilique 250/35 micrograms tablets
Active SubstancesNorgestimate
Dosage FormTablet
Licence HolderConsilient Health Limited
Licence NumberPA1876/003/001

Group Information

ATC CodeG03AA Progestogens and estrogens, fixed combinations
G03AA11 norgestimate and ethinylestradiol


License statusAuthorised
Licence Issued11/12/2015
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - HCP

Educational Materials - Patient

« Back